Australia’s trusted immunisation experts
02 November 2022 | NewsAt least two thirds of Australians, including children and adolescents, have had COVID-19, two national antibody studies findRead the full article
AstraZeneca COVID-19 vaccine Vaxzevria is associated with a very rare risk of a condition called thrombosis with thrombocytopenia syndrome, or TTS.
TTS involves blood clots (thrombosis) along with low platelet levels (thrombocytopenia), and occurs around 4-28 days after vaccination. It is currently estimated to affect around 6 people per million doses. To date, almost all reported cases were after the first dose of the vaccine.
Several resources are available to provide information to immunisation providers about TTS following vaccination with COVID-19 Vaccine AstraZeneca.
We have answered commonly asked questions about thrombosis with thrombocytopenia syndrome following COVID-19 Vaccine AstraZeneca on our COVID-19 vaccines: Frequently asked questions webpage. Access these and other questions and answers about COVID-19 vaccines here.